Business
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
Key combination for the treatment of first-line AMLRecent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and azacitidine MADRID and CAMBRIDGE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. pate
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aIzIc6M4qMfpzqoj73eV3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzOA--/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Key combination for the treatment of first-line AML","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Recent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and azacitidine ","length":157,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":208,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent US12,564,559 B2, relating to therapeutic combinations of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology.","length":470,"tagName":"p"},{"type":"text","content":"The granted patent includes claims covering methods of treating neoplastic diseases, including acute myeloid leukemia (AML), using combinations comprising iadademstat and other therapeutic agents, notably including venetoclax, a backbone therapy in the current standard of care for first-line acute myeloid leukemia.","length":316,"tagName":"p"},{"type":"text","content":"The patent is expected to expire in January 2039, including 681 days of patent term adjustment (PTA) granted by the USPTO to compensate for delays during patent prosecution. This does not include any potential patent term extension related to regulatory review, which could further extend the patent term.","length":305,"tagName":"p"},{"type":"text","content":"Iadademstat is currently being evaluated in seven ongoing oncology clinical trials, including the Phase Ib ALICE-2 study in first-line AML in combination with...